Mechanistic Investigations into ADRD Multiple Etiology Dementias (R01 - Clinical Trial Not Allowed) | PAR 24 147

FAQs: Mechanistic Investigations into ADRD Multiple Etiology Dementias (R01 - Clinical Trial Not Allowed) (PAR-24-147)

What is this funding opportunity?

This opportunity is an NIH R01 research grant (PAR-24-147) focused on Alzheimer’s disease and related dementias (ADRD) where more than one disease process contributes to neurodegeneration and clinical decline. It supports mechanistic, hypothesis-driven studies that explain how interacting co-occurring brain pathologies worsen disease biology and outcomes compared to a single pathology alone.

What is the main goal of the program?

The central goal is to fund studies that move beyond documenting that mixed pathologies co-exist and instead identify the cellular and molecular mechanisms by which at least two etiologic processes interact to amplify damage, accelerate neurodegeneration, and produce more severe or different clinical phenotypes.

What kind of science is emphasized: descriptive or mechanistic?

The program emphasizes mechanistic, hypothesis-driven research. Projects are expected to explain why and how co-pathologies interact, rather than only reporting that multiple pathologies are present in the same brain or cohort.

How many co-pathologies are required?

Proposed projects must include a minimum of two relevant co-pathologies.

Which co-pathologies are specifically mentioned as examples?

Examples named include tau, alpha-synuclein, TDP-43, TMEM106B-related biology, and vascular contributions. Applicants may also propose other well-justified co-pathologies when appropriate.

Can a project include additional risk factors or co-morbidities?

Yes. Risk factors and co-morbidities are optional additions. Investigators may include factors such as genetic risk, metabolic disease, inflammation, cerebrovascular risk, or other clinical co-conditions if they strengthen the mechanistic rationale. The primary emphasis remains on how multiple etiologic processes intersect to drive disease biology and shape phenotypes.

What types of mechanistic interactions is NIH looking for?

The opportunity is looking for cellular and molecular explanations for how co-occurring pathologies amplify damage when they appear together. This includes work that can map causal chains and interaction points between etiologies, rather than treating them as independent processes.

Is there a preference for studying specific cells, circuits, or brain regions?

Yes. The scientific scope prioritizes studies that examine how co-pathologies interact in specific cells and circuits over time, rather than treating the brain as uniform tissue. Projects are encouraged to look across brain regions and disease stages.

What does “cellular proximity” mean in this context?

The announcement encourages focusing on proximate cell populations where interacting pathologies could realistically influence one another, such as within the same neuron, within neuron-glia neighborhoods, or along connected neural networks.

Does the opportunity emphasize intracellular mechanisms?

Yes. The NOFO highlights intracellular dynamics and localization, including where pathogenic proteins and related processes are within cells, how they traffic, seed, spread, or disrupt organelles, and how those processes change as disease progresses.

Are studies limited to aggregated protein states?

No. A stated priority is investigating events both upstream and downstream of aggregated protein states. The program is interested in mechanisms occurring before visible aggregates form and also in consequences that follow aggregation.

What are examples of “upstream” events the program is interested in?

Examples include early misfolding, impaired clearance, post-translational modifications, stress responses, and changes in RNA/protein homeostasis that occur before visible aggregates are detected.

What are examples of “downstream” events the program is interested in?

Examples include synaptic dysfunction, inflammatory activation, vascular impairment, cell death pathways, and network-level dysfunction that occur after aggregation and contribute to clinical decline.

What outcomes or endpoints does the program want the research to connect to?

The intent is to identify sequences of events that explain why mixed proteinopathies or mixed etiologies lead to worse cognitive, behavioral, and neurologic outcomes, and to pinpoint mechanistic links that could become targets for future interventions.

What grant mechanism is used?

This is an NIH R01 research project grant mechanism.

Are clinical trials allowed under this opportunity?

No. The opportunity is designated “Clinical Trial Not Allowed,” so funded work should be basic, translational, or preclinical in nature rather than testing interventions in humans as clinical trials.

Does the program allow translational or preclinical studies?

Yes. Because clinical trials are not allowed, the supported work is expected to be basic, translational, or preclinical, focused on mechanistic understanding rather than clinical intervention testing in humans.

What is the referenced award ceiling?

The listing includes an award ceiling of $500,000 (as referenced in the provided source summary).

What is the original closing date listed?

The original closing date listed is 2024-10-04.

Which NIH/CFDA areas are associated with this opportunity?

The opportunity sits within NIH’s health research portfolio and is associated with CFDA 93.853 and 93.866.

Who is eligible to apply within the United States?

Eligibility is broad and includes many types of domestic U.S. organizations, including public and private institutions of higher education, state and local governments, federally recognized tribal governments, certain tribal organizations, independent school districts, special district governments, public housing authorities/Indian housing authorities, nonprofits (with or without 501(c)(3) status), for-profit organizations (other than small businesses), and small businesses.

Are specific institution types explicitly called out as eligible?

Yes. The NOFO explicitly calls out Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal agencies, regional organizations, and U.S. territories or possessions.

Can a non-U.S. (foreign) organization apply as the applicant?

No. Non-domestic (non-U.S.) entities are not eligible to apply as the applicant organization.

Can a non-domestic component of a U.S. organization apply?

No. Non-domestic components of U.S. organizations are also not eligible to apply as the applicant.

Are foreign components allowed at all?

Yes. Foreign components are allowed as defined in the NIH Grants Policy Statement. A U.S.-based applicant may include well-justified collaborations or project elements conducted abroad if they meet NIH’s rules for foreign components and are scientifically necessary.

What distinguishes a strong application concept under this NOFO?

Based on the stated priorities, stronger concepts are those that: (1) include at least two co-pathologies; (2) test mechanistic hypotheses about how the processes intersect; (3) resolve interactions across time, brain regions, and disease stages; (4) focus on realistic cellular proximity and intracellular localization; and (5) address upstream and/or downstream events around aggregation to explain worsened neurodegeneration and altered phenotypes in mixed etiologies.